AMENDMENTS TO THE CLAIMS

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing. This listing of claims will replace all prior versions and listings of claims in the application:

- 1-39. (Canceled).
- 40. (Currently Amended) A method for stimulating a subject's response to a vaccine comprising administering an immunostimulatory oligonucleotide adjuvant as a vaccine adjuvant with the vaccine to the subject to stimulate the subject's response to the vaccine, wherein the immunostimulatory oligonucleotide comprises a phosphate backbone modification and greater than two unmethylated cytosine-guanine dinucleotides, and wherein the oligonucleotide is at least eight nucleotides in length The method of elaim 37, wherein the oligonucleotide is linked to a nucleic acid delivery complex.
- 41. (Previously Presented) The method of claim 40, wherein the nucleic acid delivery complex is a cationic lipid.
- 42. (Previously Presented) The method of claim 40, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.
- (Previously Presented) The method of claim 40, wherein the oligonucleotide is ionically linked to or encapsulated in the nucleic acid delivery complex.
- (Previously Presented) The method of claim 40, wherein the nucleic acid delivery complex is a sterol.
 - 45-53. (Canceled).

3 Docket No.: C1039.70083US05

Application No. 10/789,536 Amendment dated August 9, 2011 After Final Office Action of May 24, 2011

- 54. (Previously Presented) A method for stimulating a subject's response to a vaccine comprising administering an immunostimulatory oligonucleotide adjuvant as a vaccine adjuvant with the vaccine to the subject to stimulate the subject's response to the vaccine, wherein the immunostimulatory oligonucleotide comprises a phosphate backbone modification and an unmethylated cytosine-guanine dinucleotide, wherein the oligonucleotide is at least eight nucleotides in length and wherein the unmethylated cytosine-guanine dinucleotide is flanked by two 5' purines and two 3' pyrimidines.
- 55. (Previously Presented) The method of claim 54, wherein the oligonucleotide includes at least two unmethylated cytosine-guanine motifs.
- 56. (Previously Presented) The method of claim 55, wherein at least one of the at least two unmethylated cytosine-guanine motifs is not palindromic.